The FDA on December 4, 2025, approved BREYANZI® for adults with relapsed or refractory Marginal Zone Lymphoma (MZL) who have received at least two prior lines of systemic therapy. BREYANZI® is a product of Juno Therapeutics, Inc., a Bristol-Myers Squibb Company.
Bottom Ad
Advertisement
Subscribe
